Topic

Articles

With this acquisition, Merck KGaA will have the capability to offer integrated services for viral vector manufacturing.

Merck KGaA Announces $600 Million Deal to Acquire Mirus Bio

Cheryl Barton is director of PharmaVision, 

Novel delivery technologies enhance brain penetration to target neurodegenerative diseases and glioblastomas.

Frontrunners in CNS Drug Delivery

Feliza Mirasol is the science editor for 

ProPharm and PBL have introduced a fully automated, enclosed cell factory manufacturing device.

New Cell Factory Box Launched by ProPharma and PBL for Automated CGT Manufacturing 

The two companies will combine their cell therapy platforms to develop convertibleCAR programs targeting solid tumors.

Poseida Therapeutics and Astellas to Develop Novel Allogeneic Cell Therapies

Mike Hennessy Jr. is the President and CEO of 

Technological advances are helping advance biologics development and manufacturing and reduce bottlenecks.

Tapping into the Potential of Biologics

SK pharmteco, a CDMO, will manufacture, test, and release Adstiladrin (nadofaragene firadenovec-vncg), a gene therapy from Ferring Pharmaceuticals for treating bladder cancer.

SK pharmteco to Ensure Supply of Ferring Pharmaceuticals Gene Therapy

In a new agreement, Cellares will utilize its Cell Shuttle fully automated cell therapy manufacturing platform to manufacture select CAR-T cell therapies under development by Bristol Myers Squibb. 

Bristol Myers Squibb to Access Cellares' Cell Therapy Manufacturing Platform in New $380 Million CAR-T Cell Therapy Deal

Charles River has entered into separate agreements with Axovia Therapeutics and Ship of Theseus to offer plasmid DNA manufacturing services for a gene therapy and a lead candidate program, respectively.

Charles River to Provide pDNA Manufacturing Services in Two Deals

Under a collaboration agreement, Lonza will manufacture sabirnetug, Acumen Pharmaceuticals' mAb in clinical development for treating Alzheimer’s disease.

Lonza Forms Agreement to Manufacture Acumen Pharmaceuticals’ AD mAb Therapy 

Genmab's acquisition of ProfoundBio will boost its clinical and preclinical pipeline of ADCs for targeted cancer treatment.

Deals, Development and Manufacturing